YaoGeJu

Public drug landscapesDrug landscape

Tafluprost Eye Drops

As of 16 November 2026, for Tafluprost Eye Drops, 3 applications are listed as under review at China's CDE; 2 companies have filed new generic applications in 2026; the chemical-drug catalogue lists 1 holder.

Companies, stages and changes, with each record available on this page.

Listed in the US FDA Orange Book as ZIOPTAN (NDA 202514, THEA PHARMA INC).

Last 90 days: Accepted: 2 applications

Current coverage may be incomplete

Track this drug free

Free: up to 3 drugs, Monday digest. Sign in with Google or an email code. No card needed.

Complete CDE snapshot
2026/11/16 06:38
Matching scope
Same generic name; dosage forms and combinations kept separate

US Orange Book listing

The brand names come from the US FDA Orange Book and describe US listing records for this active ingredient. They do not indicate that products under these brand names are approved or sold in China, or that Chinese applicants are affiliated with US holders.

Orange Book source export date: 2026/11/06. Version: 2026-11-06.

Showing 1 of 1 distinct brand names.

A brand with different source forms or statuses can appear on multiple rows and in both groups. Distinct brand names are counted once globally, with a limit of five.

Verified official English dosage form: Eye Drops. Listings are grouped by the source dosage form and route; records without a clear correspondence are listed in the other group. Grouping does not establish product equivalence.

Same dosage form

Brand nameApplicant (source text)Application numberDosage form (source text)Route (source text)Marketing status (source text)Approval date
ZIOPTAN THEA PHARMA INC NDA 202514 · Product no. 001 SOLUTION/DROPS OPHTHALMIC HUMAN PRESCRIPTION DRUG 2012/02/10

Other dosage forms of the same ingredient

No listings in this group among the displayed brand names.

Same-form/route listings come first, followed by other forms/routes. Within each group, source prescription/OTC listings precede discontinued listings; unknown statuses are last. Each status bucket is ordered by earliest approval date, ascending: pre-1982 records first, missing dates last; ties by brand name, application number and product number. The first five distinct brands in this order are selected globally. All retained source facts for those brands are shown in their own groups; a brand spanning both groups counts once.

Ingredient cross-list details ↗

Which companies are listed, and at what stages?

Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.

Chemical-drug catalogue

Loaded records: 1 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 0 in the new chemical-registration-classification generic category. Category counts may overlap.

Marketing authorization holderManufacturerApproval numberApprovedStrength / specificationCatalogue category (source text)View source
Santen Pharmaceutical Co.,Ltd.Santen Pharmaceutical Co.,Ltd.Shiga PlantH201504232015/07/270.0015%(2.5ml:37.5μg)Imported originator drugCDE

Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.

NHSA drug codes

Loaded records: 13 distinct approval numbers and 11 companies.

Company / applicantApproval numberStrength / specificationNHSA classNHSA drug codeView source
Shenyang Xing Qi Yan Yao Co., Ltd. romanized国药准字H202531640.0015%(0.3ml:4.5μg)Category BXS01EET161G010010101322NHSA
Yangtze River Pharmaceutical Group Co., Ltd国药准字H202436900.0015%(0.3ml:4.5μg)Category BXS01EET161G010010101749NHSA
Hangzhou Minsheng Pharmaceutical Co., Ltd国药准字H202448550.0015%(2.5ml∶37.5μg)Category BXS01EET161G010010104494NHSA
Zhejiang Jian Feng Pharma Co., Ltd. romanized国药准字H202435900.0015%(2.5ml: 37.5μg)Category BXS01EET161G010010104655NHSA
Hainan Si Da Pharmaceutical Co., Ltd. romanized国药准字H202560770.0015%(0.3ml:4.5μg)Category BXS01EET161G010010105816NHSA
Santen Pharmaceutical Co., Ltd.国药准字J201501310.0015%(2.5ml:37.5μg)Category BXS01EET161G010010109591NHSA
Santen Pharmaceutical Co.,Ltd.国药准字HJ201910240.0015%(0.3ml:4.5μg)Category BXS01EET161G010010178986NHSA
Chengdu Sheng Di Pharmaceuticals Co., Ltd. romanized国药准字H202138550.0015%(0.3ml:4.5μg)Category BXS01EET161G010010180435NHSA
Shaanxi Li Cai Pharma Co., Ltd. romanized国药准字H202449140.0015%(0.3ml:4.5μg)Category BXS01EET161G010010183540NHSA
Suzhou Ou Kang Wei Shi Bio Technology Co., Ltd. romanized国药准字H202533590.0015%(0.3ml:4.5µg)Category BXS01EET161G010010183562NHSA
Jiangsu An Bi Sheng Pharmaceutical Co., Ltd. romanized国药准字H202545640.0015%(0.3ml:4.5μg)Category BXS01EET161G010010183683NHSA
Hubei Min Kang Pharma Group Co., Ltd. romanized国药准字H202560670.0015%(0.3ml:4.5μg)Category BXS01EET161G010010184564NHSA
Hainan Si Da Pharmaceutical Co., Ltd. romanized国药准字H202560770.0015%(0.3ml:4.5μg)Category BXS01EET161G010010205816NHSA
Santen Pharmaceutical Co.,Ltd.国药准字HJ201910240.0015%(0.3ml:4.5μg)Category BXS01EET161G010010278986NHSA
Chengdu Sheng Di Pharmaceuticals Co., Ltd. romanized国药准字H202138550.0015%(0.3ml:4.5μg)Category BXS01EET161G010010280435NHSA
Chengdu Sheng Di Pharmaceuticals Co., Ltd. romanized国药准字H202138550.0015%(0.3ml:4.5μg)Category BXS01EET161G010010380435NHSA
Santen Pharmaceutical Co.,Ltd.国药准字HJ201505280.0015%(2.5ml:37.5μg)Category BXS01EET161G010020178986NHSA

Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.

Current under-review applications

Loaded records: 3 filings and 3 distinct first applicants.

Generic 3

Current under-review applications
Company / applicantAcceptance numberApplication typeAcceptedStrength / specificationView source
Shandong Chen Xin Fu Dou Pharma Co., Ltd. romanizedCYHS2503857Generic2025/11/03Not stated by sourceCDE
Hong Yue Technology (Hu Zhou) Co., Ltd. romanized; Hangzhou Minsheng Pharmaceutical Co., LtdCYHS2602797Generic2026/11/12Not stated by sourceCDE
Chongqing Ke Rui Pharmaceutical (Group) Co., Ltd. romanizedCYHS2602796Generic2026/11/12Not stated by sourceCDE
New generic filings in 2026

Loaded records: 2 filings and 2 distinct first applicants.

New generic filings in 2026
Company / applicantAcceptance numberApplication typeAcceptedStrength / specificationView source
Hong Yue Technology (Hu Zhou) Co., Ltd. romanized; Hangzhou Minsheng Pharmaceutical Co., LtdCYHS2602797Generic2026/11/12Not stated by sourceCDE
Chongqing Ke Rui Pharmaceutical (Group) Co., Ltd. romanizedCYHS2602796Generic2026/11/12Not stated by sourceCDE
API registrations

Non-component matches: 5 companies with A status and 1 I-status records. Component matches are listed separately and excluded from these counts.

NameCompany / applicantRegistration numberStatusName matchSource update dateView source
他氟前列素 · No verified English nameZhejiang Ao Xiang Pharma Co., Ltd. romanizedY20220000747AExact ingredient2026/09/24CDE
他氟前列素 · No verified English nameJia He Gui Technology Co., Ltd. You Shi Factory romanizedY20210000395AExact ingredient2024/02/08CDE
他氟前列素 · No verified English nameYang Zi Jiang Pharma Group Jiangsu Hai Ci Bio Pharma Co., Ltd. romanizedY20210000367AExact ingredient2023/06/12CDE
他氟前列素 · No verified English nameZhejiang Jian Feng Pharma Co., Ltd. romanizedY20210000093AExact ingredient2023/08/16CDE
他氟前列素 · No verified English nameZhejiang Tian Yu Pharma Co., Ltd. romanizedY20190000507AExact ingredient2026/08/15CDE
他氟前列素 · No verified English nameXu Xiao Zi Zhu Shi Hui She romanizedY20170001527IExact ingredient—CDE

A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.

What changed recently?

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.

Trial registration does not mean an application will follow.

This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.

NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/16 06:35. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.

  1. 2026/11/12Accepted

    Hong Yue Technology (Hu Zhou) Co., Ltd. romanized; Hangzhou Minsheng Pharmaceutical Co., Ltd

    CYHS2602797

    Fact date: 2026/11/12 · Site observation date: 2026/11/13

    View source ↗
  2. 2026/11/12Accepted

    Chongqing Ke Rui Pharmaceutical (Group) Co., Ltd. romanized

    CYHS2602796

    Fact date: 2026/11/12 · Site observation date: 2026/11/13

    View source ↗

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/16 06:38
Chemical-drug catalogue
Last successful update: 2026/11/16 06:35

Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.

Full API register
Last successful update: 2026/11/16 06:37
NHSA drug codes
Last successful update: 2026/11/05 06:45

The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.

NMPA drug delivery notices
Last successful update: 2026/11/15 18:30

First index-page publication dates: 2026-10-29 to 2026-11-13; 0 pages pending. Covers loaded notices only, not a complete historical approval database.

Drug Clinical Trial Registry and Information Disclosure Platform
Last successful update: 2026/11/16 08:10 · Current coverage may be incomplete

Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.

This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.

Public-product searches scanned: 11/30; discovered pending details: 9. Record counts in unscanned portions remain unknown.

Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.

Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

Free follow

Follow changes to Tafluprost Eye Drops

Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.

Confirmation links expire in 7 days. No digest is sent before confirmation; existing follows are not duplicated.

Sign in to choose products

The China drug-review weekly, by email every Monday

No account needed.

Covers all drugs in the loaded CDE records, not only this one: weekly acceptance counts, top-10 lists and definitions. View the latest report

A text version of this report, weekly, in the language you subscribe in. You will receive one confirmation email first; sending starts only after you click its link. Every issue carries an unsubscribe link.